Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 3, 2012, Pages 211-216

  Gomes, Valéria A ^a   Vieira, Carolina S ^b,c   Jacob Ferreira, Anna L ^a   Belo, Vanessa A ^a   Soares, Gustavo M ^b   França, Janaína B ^b   Ferriani, Rui A ^b,c   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c National Institute of Hormones and Women's Health   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; GELATIN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANTHROPOMETRY; BRAZIL; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; POLYCYSTIC OVARY SYNDROME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; YOUNG ADULT;

EID: 84865110933     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00895.x     Document Type: Article

References (52)

1. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691-7.
2. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008;93:82-90.
3. Gonzalez F, Rote NS, Minium J, Kirwan JP Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009;58:954-62.
4. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20:2409-13.
5. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588-93.
6. Soares GM, Vieira CS, Martins WP, Franceschini SA, dos Reis RM, Silva de Sa MF, et al. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol (Oxf) 2009;71:406-11.
7. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.
8. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-61.
9. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.
10. Galis ZS, Khatri JJ Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62.
11. Liapis CD, Paraskevas KI The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. Vasc Med 2003;8:267-71.
12. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003;33:648-56.
13. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000;31:40-7.
14. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
16. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001;89:201-10.
17. Fatar M, Stroick M, Griebe M, Hennerici M Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005;20:141-51.
18. van den Borne SW, Cleutjens JP, Hanemaaijer R, Creemers EE, Smits JF, Daemen MJ, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009;18:37-43.
19. Liu B, Cai LY, Lv HM, Xia L, Zhang YJ, Zhang HX, et al. Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecol Endocrinol 2008;24:285-8.
20. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papassotiriou I Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur J Endocrinol 2008;158:525-31.
21. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:1173-7.
22. Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, Fernandes JB, et al. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Mol Cell Biochem 2011;353:251-7.
23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 2004;19:41-7.
24. Organization WH. Medical Eligibility Criteria for Contraceptive Use. Organization WH, editor, World Health Organization, 2009.
25. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Mathur RS, Moody LO, Landgrebe S, Williamson HO Plasma androgens and sex hormone-binding globulin in the evaluation of hirsute females. Fertil Steril 1981;35:29-35.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
28. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005;38:410-4.
29. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-9.
30. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-23.
31. Norman RJ, Dewailly D, Legro RS, Hickey TE Polycystic ovary syndrome. Lancet 2007;370:685-97.
32. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-9.
33. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007;22:3197-203.
34. Vrbikova J, Cibula D Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005;11:277-91.
35. Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. Reprod Sci 2010;17:767-75.
36. Marcal DM, Rizzi E, Martins-Oliveira A, Ceron CS, Guimaraes DA, Gerlach RF, et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011;383:35-44.
37. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM, et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-30.
38. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
39. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus-Santos JE Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2011;383:547-54.
40. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006;47:117-22.
41. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003;144:1656-63.
42. Li BY, Liao XB, Fujito A, Thrasher JB, Shen FY, Xu PY Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J Androl 2007;9:41-50.
43. Henmi H, Endo T, Nagasawa K, Hayashi T, Chida M, Akutagawa N, et al. Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biol Reprod 2001;64:157-62.
44. Natoli AK, Medley TL, Ahimastos AA, Drew BG, Thearle DJ, Dilley RJ, et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. Hypertension 2005;46:1129-34.
45. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010;29:194-201.
46. Guimaraes DA, Rizzi E, Ceron CS, Oliveira AM, Oliveira DM, Castro MM, et al. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011;108:318-25.
47. Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R Jr, Rossi MA, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail. 2010;16:599-608.
48. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens 2012;26:171-7.
49. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, et al. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 2012;36:69-75.
50. Goncalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009;403:173-7.
51. Marson BP, Lacchini R, Belo V, Dickel S, Da Costa BP, Poli de Figueiredo CE, et al. Matrix Metalloproteinase (MMP)-2 Genetic Variants Modify the Circulating MMP-2 Levels in End-Stage Kidney Disease. Am J Nephrol 2012;35:209-15.
52. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Duarte G, et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp Mol Pathol 2012;92:217-21.